Biogen

Massachusetts
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Biogen scored a 100 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Biogen increases the risk of dividing employees, alienating customers and harming shareholders. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Biogen forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Biogen provides a benefits package for employees which covers travel/lodging costs for an abortion and transgender medical procedures for covered employees and dependents, including children. The company supports the Equality Act and signed an amicus brief opposing Catholic Social Services in the Fulton v. Philadelphia Supreme Court case. The company's CEO signed the CEO Action for Diversity and Inclusion pledge. Biogen opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. The company signed an amicus brief in opposition to the 2016 North Carolina bathroom bill HB2, which required people to use the bathroom of their biological sex. Biogen signed the Health Sector Climate Pledge, committing itself to achieve net zero emissions by 2050. For these reasons, Biogen receives a High Risk rating.

View Full Report
Generate Reports
Clear
Toast